Hepatitis A virus (HAV) infection is a worldwide health problem, but rarely causes fatal fulminan hepatitis. HAV infection in patients with chronic liver diseases is associated with increased rate of fulminan hepatitis and mortality. Vaccination against HAV is recommended for patients with underlying chronic liver disease who are negative for anti-HAV antibody. In this study, a total of 780 patients (680 inactive hepatitis B virus carrier, 62 chronic hepatitis C, 34 chronic hepatitis B, 4 chronic hepatitis D) were tested for the presence of anti-HAV total antibody. Anti-HAV seroprevalence was found 93.7%.